Is militizumab effective in treating intestinal ulcers?

Milikizumab (Mirikizumab) is an innovative humanized IgG4 monoclonal antibody that targets the IL-23p19 subunit. By inhibiting this inflammatory pathway, it effectively blocks a variety of cytokines involved in the intestinal mucosal immune response. It has shown significant clinical value in the treatment of Ulcerative Colitis (UC). Compared with traditional immunosuppressants and corticosteroid drugs, militizumab has a more precise mechanism of action. It can effectively control the inflammatory response and promote the healing of the intestinal mucosa without extensively suppressing the immune system, thereby achieving the goals of relieving symptoms, preventing recurrence, and improving quality of life.

Supported by data from multiple international studies that have been published, militizumab has a good effect on inducing and maintaining remission in patients with moderate to severe ulcerative colitis. Especially in refractory patients, it also shows a high response rate. This advantage is of great significance for the optimization of clinical treatment plans. Since the IL-23 pathway has been found to play a key role in multiple chronic inflammatory diseases, the successful application of militizumab as an IL-23 inhibitor in ulcerative colitis has also expanded its potential application prospects in other related diseases.

It is worth noting that the safety of militizumab has also been highly evaluated. Compared with other biological agents, its common adverse reactions are mild, mainly injection site reactions, minor infections or headaches, and serious immune-related side effects are less common. Therefore, it becomes one of the most promising biopharmaceutical options in the current treatment of ulcerative colitis. Militizumab provides a new treatment path for patients who have a poor response to or are intolerant to TNF-α inhibitors.

Reference materials:https://omvoh.lilly.com/